vTv Therapeutics Inc (NASDAQ:VTVT) major shareholder Ronald O. Perelman purchased 1,358,698 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The shares were purchased at an average cost of $1.84 per share, for a total transaction of $2,500,004.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
VTVT opened at $1.45 on Thursday. vTv Therapeutics Inc has a fifty-two week low of $0.68 and a fifty-two week high of $6.09. The stock has a market cap of $75.27 million, a P/E ratio of -2.10 and a beta of -3.79.
vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($0.26) EPS for the quarter. The business had revenue of $0.92 million for the quarter. On average, research analysts predict that vTv Therapeutics Inc will post -0.59 EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the business. Wedbush Securities Inc. bought a new stake in vTv Therapeutics in the first quarter worth about $30,000. Morgan Stanley raised its position in vTv Therapeutics by 147,061.5% in the first quarter. Morgan Stanley now owns 19,131 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 19,118 shares during the period. Barclays PLC raised its position in vTv Therapeutics by 366.7% in the fourth quarter. Barclays PLC now owns 28,000 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 22,000 shares during the period. D. E. Shaw & Co. Inc. bought a new stake in vTv Therapeutics in the fourth quarter worth about $186,000. Finally, Sabby Management LLC bought a new stake in vTv Therapeutics in the first quarter worth about $382,000. 1.16% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently weighed in on VTVT shares. Zacks Investment Research lowered shares of vTv Therapeutics from a “buy” rating to a “hold” rating and set a $2.75 price target on the stock. in a research report on Saturday, January 19th. Northland Securities reissued a “hold” rating and set a $3.00 price target on shares of vTv Therapeutics in a research report on Wednesday, February 27th.
About vTv Therapeutics
vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease.
Further Reading: Stock Split
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.